

October 15, 2025

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma)

We refer to our earlier communication dated March 6, 2025, intimating the receipt of Import and Marketing Permission in Form CT-20 from the Drugs Controller General of India for Sodium Zirconium Cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma).

With regard to the same, we wish to further update that AstraZeneca Pharma India Limited will launch Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in November 2025 in India.

Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients.

We request you to take the above intimation on record.

Thanking you

For **AstraZeneca Pharma India Limited**

Manasa. R

Company Secretary